Login
$CLRB
$1.10 -$0.04 (3.95%) Live

$CLRB SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM)

10 Nov 2026 10-Q
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G
13 Aug 2026 SCHEDULE 13G
13 Aug 2026 8-K: Results of Operations and Financial Condition

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

13 Aug 2026 10-Q
04 Aug 2026 SCHEDULE 13G
10 Jul 2026 Form 4/A: Loren Stefan, Consultant

Granted 15,000 Stock option (right to buy)

10 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this 2021 Stock Incentive Plan (the “Plan”) is to encourage and enable officers and employees of, and other persons providing services to, Cellectar Biosciences, Inc. (the “Company”) and its Subsidiaries (as defined below)...

08 Jul 2026 Form 4: Kolean Chad J, CFO

Granted 92,000 Stock option (right to buy)

08 Jul 2026 Form 4: Driscoll Frederick W, Director

Granted 25,000 Stock option (right to buy)

08 Jul 2026 Form 4: Chanan-Khan Asher, Director

Granted 25,000 Stock option (right to buy)

08 Jul 2026 Form 4: Caruso James V, Director

Granted 250,000 Stock option (right to buy)

08 Jul 2026 Form 4: Gu Andrew, Director

Granted 25,000 Stock option (right to buy)

08 Jul 2026 Form 4: Longcor Jarrod, Chief Operating Officer

Granted 118,000 Stock option (right to buy)

08 Jul 2026 Form 4: Swirsky Douglas J, Director

Granted 37,500 Stock option (right to buy)

08 Jul 2026 Form 4: Neis John, Director

Granted 25,000 Stock option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support